Date Title
May 29, 2019
May 16, 2019
Realm Therapeutics Announces Company to be Acquired by ESSA Pharma Transaction Expected to be Completed by Mid-2019
Acquisition Expected to be Completed by Mid-Year 2019 VANCOUVER and   HOUSTON, May 16, 2019 /PRNewswire/ - ESSA Pharma Inc. (" ESSA " or  "the Company ") (NASDAQ:  EPIX ; TSX-V: EPI) announced today that it has entered into a definitive  agreement with Realm Therapeutics plc (" Realm ") (NASDAQ: 
April 10, 2019
Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F Filing
MALVERN, Pa. , April 10, 2019 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM) today announces that its 2018 Annual Report is now available on the Company's website, www.realmtx.com , and will be posted to those shareholders who have not elected to receive the document electronically.  Today
April 5, 2019
Realm Therapeutics Announces Receipt of Nasdaq Listing Determination and Requests Hearing
MALVERN, Pa., April 5, 2019 /PRNewswire/ --  Realm Therapeutics plc (Nasdaq: RLM) (the "Company") today announced that the Company received written notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the Company's recent
March 29, 2019
Realm Therapeutics Announces Completion of Assets Disposal
MALVERN, Pa., March 29, 2019 /PRNewswire/ --   Realm Therapeutics plc (NASDAQ: RLM) today announces the completion of its previously announced Assets Disposal representing certain assets, which comprise the Vashe ®  wound care royalty stream, an FDA 510(k)-cleared anti-itch hydrogel, which was
March 26, 2019
Realm Therapeutics Announces Cancellation of AIM Listing
MALVERN, Pa. , March 26, 2019 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration HOCl, announced on March 15, 2019 that the listing of the Company's Ordinary Shares on AIM will cease
March 15, 2019
Realm Therapeutics Announces Result of General Meeting
All Resolutions Passed Reminder: Process to Convert Ordinary Shares into ADSs MALVERN, Pa. , March 15, 2019 /PRNewswire/ --  Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration HOCl, announces that at
November 29, 2018
Realm Therapeutics Provides Update on Strategic Review
MALVERN, Pa. , Nov. 29, 2018 /PRNewswire/ --  Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), today provides an update on timing of the ongoing formal sale process as part
September 17, 2018
Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale Process

MALVERN, Pa. , Sept. 17, 2018 /PRNewswire/ --  Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), today provides a corporate update following the August 14, 2018 announcement

August 14, 2018
Realm Therapeutics Reports Top-line Data from Phase 2 Trial of PR022 in Atopic Dermatitis and First Half 2018 Financial Results

Company Hosting Conference Call Today at 9:00 AM ET / 2:00 PM BST MALVERN, Pa. , Aug. 14, 2018 /PRNewswire/ --  Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today reports preliminary

Displaying 11 - 20 of 38

Search Investor Relations